Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanthanum carbonate vs Sevelamer hydrochloride in ESRD
NCT00151918Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2005
- Primary completion
- Aug 2005
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of lanthanum carbonate in hyperphosphatemia (2 arms), sponsored by Takeda. Primary endpoint: Mean pre-dialysis serum phosphate level. Started Jan 2005; status: completed.
02
Drugs
lanthanum carbonate
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT00151918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00151918.